{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:49:51Z","timestamp":1777384191405,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1245\/s10434-022-12095-x","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T14:02:51Z","timestamp":1659708171000},"page":"8373-8382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Local Therapy for Oligoprogression or Consolidation in High Mutational Burden Stage 4 Colorectal Cancer Treated With PD-1 or PD-L1 Blockade"],"prefix":"10.1245","volume":"29","author":[{"given":"Nicholas D.","family":"Klemen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin M.","family":"Court","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Clara","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry S.","family":"Walch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid K.","family":"Chatila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily V.","family":"Saadat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Maron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Crane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinru","family":"Shia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Cercek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mithat","family":"G\u00f6nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus D.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Garcia Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael I.","family":"D\u2019Angelica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"12095_CR1","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318.","journal-title":"N Engl J Med."},{"key":"12095_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773\u20139.","journal-title":"J Clin Oncol."},{"key":"12095_CR3","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182\u201391.","journal-title":"Lancet Oncol."},{"key":"12095_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","volume":"33","author":"R Yaeger","year":"2018","unstructured":"Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell. 2018;33:125-36.e3.","journal-title":"Cancer Cell."},{"key":"12095_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.6004\/jnccn.2017.0016","volume":"15","author":"J Gong","year":"2017","unstructured":"Gong J, Wang C, Lee PP, et al. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. J Natl Comp Cancer Netw. 2017;15:142\u20137.","journal-title":"J Natl Comp Cancer Netw."},{"key":"12095_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0672-3","volume":"7","author":"ND Klemen","year":"2019","unstructured":"Klemen ND, Wang M, Feingold PL, et al. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. J Immunother Cancer. 2019;7:1\u20139.","journal-title":"J Immunother Cancer."},{"key":"12095_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jnci\/djaa052","volume":"113","author":"K Ludford","year":"2021","unstructured":"Ludford K, Cohen R, Svrcek M, et al. Pathological tumor response following immune checkpoint blockade for deficient mismatch-repair advanced colorectal cancer. J Natl Cancer Inst. 2021;113:208\u201311.","journal-title":"J Natl Cancer Inst."},{"key":"12095_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. JMD J Mol Diagn. 2015;17:251\u201364.","journal-title":"JMD J Mol Diagn."},{"key":"12095_CR9","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med."},{"key":"12095_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703\u201313.","journal-title":"Nat Med."},{"key":"12095_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.17.00011","volume":"1","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology knowledge base. JCO Precision Oncol. 2017;1:1\u201316. https:\/\/doi.org\/10.1200\/po.17.00011.","journal-title":"JCO Precision Oncol."},{"key":"12095_CR12","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin D-C, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356.","journal-title":"Genome Res."},{"key":"12095_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov."},{"key":"12095_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/01.sla.0000236630.93587.59","volume":"245","author":"RP DeMatteo","year":"2007","unstructured":"DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007;245:347\u201352.","journal-title":"Ann Surg."},{"key":"12095_CR15","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","volume":"31","author":"PH Patel","year":"2019","unstructured":"Patel PH, Palma D, McDonald F, et al. The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clin Oncol. 2019;31:824\u201333.","journal-title":"Clin Oncol."},{"key":"12095_CR16","doi-asserted-by":"publisher","first-page":"20160251","DOI":"10.1259\/bjr.20160251","volume":"89","author":"P Cheung","year":"2016","unstructured":"Cheung P. Stereotactic body radiotherapy for oligoprogressive cancer. Br J Radiol. 2016;89:20160251.","journal-title":"Br J Radiol."},{"key":"12095_CR17","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1097\/JTO.0000000000000648","volume":"10","author":"H Al-Halabi","year":"2015","unstructured":"Al-Halabi H, Sayegh K, Digamurthy SR, et al. Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J Thorac Oncol. 2015;10:1601\u20137.","journal-title":"J Thorac Oncol."},{"key":"12095_CR18","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1200\/JCO.19.00709","volume":"37","author":"JC Osorio","year":"2019","unstructured":"Osorio JC, Arbour KC, Le DT, et al. Lesion-level response dynamics to programmed cell death protein (PD-1) blockade. J Clin Oncol. 2019;37:3546\u201355.","journal-title":"J Clin Oncol."},{"key":"12095_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1245\/s10434-016-5537-0","volume":"24","author":"ND Klemen","year":"2017","unstructured":"Klemen ND, Feingold PL, Goff SL, et al. Metastasectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma. Ann Surg Oncol. 2017;24:135\u201341.","journal-title":"Ann Surg Oncol."},{"key":"12095_CR20","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1245\/s10434-019-08099-9","volume":"27","author":"DM Bello","year":"2019","unstructured":"Bello DM, Panageas KS, Hollmann T, et al. Survival outcomes after metastasectomy in melanoma patients categorized by response to checkpoint blockade. Ann Surg Oncol. 2019;27:1180\u20138.","journal-title":"Ann Surg Oncol."},{"key":"12095_CR21","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2006.05.8727","volume":"24","author":"S Benoist","year":"2006","unstructured":"Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939\u201345.","journal-title":"J Clin Oncol."},{"key":"12095_CR22","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","volume":"18","author":"PA Prieto","year":"2012","unstructured":"Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039\u201347.","journal-title":"Clin Cancer Res."},{"key":"12095_CR23","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550\u20137.","journal-title":"Clin Cancer Res."},{"key":"12095_CR24","first-page":"86","volume":"4","author":"DS Lee","year":"1998","unstructured":"Lee DS, White DE, Hurst R, et al. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. Cancer J Sci Am. 1998;4:86\u201393.","journal-title":"Cancer J Sci Am."},{"key":"12095_CR25","doi-asserted-by":"publisher","first-page":"e002501","DOI":"10.1136\/jitc-2021-002501","volume":"9","author":"G Fuc\u00e0","year":"2021","unstructured":"Fuc\u00e0 G, Corti F, Ambrosini M, et al. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer. 2021;9:e002501.","journal-title":"J Immunother Cancer."},{"issue":"4","key":"12095_CR26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Haanen JB. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566\u201376.","journal-title":"Nat Med."},{"issue":"4_suppl","key":"12095_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2022.40.4_suppl.016","volume":"40","author":"MA Lumish","year":"2022","unstructured":"Lumish MA, Cohen JL, Stadler ZK, et al. PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer. J Clin Oncol. 2022;40(4_suppl):16\u201316.","journal-title":"J Clin Oncol."},{"key":"12095_CR28","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1158\/1078-0432.CCR-19-2390","volume":"26","author":"J Datta","year":"2020","unstructured":"Datta J, Smith JJ, Chatila WK, et al. Coaltered Ras\/B-raf and TP53 Is associated with extremes of survivorship and distinct patterns of metastasis in patients with metastatic colorectal cancer. Clin Cancer Res. 2020;26:1077\u201385.","journal-title":"Clin Cancer Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12095-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12095-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12095-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T20:05:12Z","timestamp":1667851512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12095-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":28,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["12095"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12095-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}